Perforin (PRF) has a key role in the function of cytotoxic T and natural killer cells. Rare variations of PRF1 predispose to autoimmunity. Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disease of the peripheral nervous system, involving defective lymphocyte apoptosis. The aim of this study was to investigate the role of PRF1 in CIDP. The entire coding region of PRF1 was sequenced in 94 patients and 158 controls. We found three missense variations leading to amino acid substitutions and one nonsense variation resulting in a premature stop codon. All variations would decrease PRF activity. Their overall frequency was significantly higher in patients than in controls (odds ratio (OR) = 4.47). The most frequent variation was p. Ala91Val (OR = 3.92) previously associated with other autoimmune diseases. Clinical analysis showed that PRF1 variations were more frequent in relapsing patients and in patients displaying axonal damage. These data suggest that PRF1 variations may influence CIDP development and course.
INTRODUCTION
Perforin (PRF) is a pore-forming protein of 67 KDa contained in granules of cytotoxic T lymphocytes (CTLs) and natural killer cells, together with granzymes. These are the main weapons used by these cells to kill their target cells as PRF forms pores on the membrane of target cells and allows the entrance of granzymes that induce cell apoptosis by activating the caspase pathway. 1 This cytotoxic activity is not only involved in the clearance of virusinfected and tumor cells but also in immune homeostasis, as 'fratricide' of activated immune cells results in shutoff of the immune response. Biallelic mutations of the PRF gene (PRF1), on chromosome 10q22, account for up to 30% of familial hemophagocytic lymphohistiocytosis cases, a rare autosomal recessive immune disorder of infants and young children, in which natural killer cell and CTL cytotoxicity is severely impaired. 2, 3 However, we suggested that monoallelic mutations of PRF1 may also work as risk factors for the development of autoimmune diseases as their frequency is increased in several autoimmune diseases, such as autoimmune lymphoproliferative syndrome 4 and its variant Dianzani autoimmune lymphoproliferative disease, 4 type 1 diabetes mellitus 5 and multiple sclerosis (MS). 6 Intriguingly, these diseases may also show the defective function of the Fas death pathway, which is another system used by the cytotoxic cells to kill target cells and is deeply involved in immune homeostasis. [7] [8] [9] [10] [11] Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disease affecting the peripheral nervous system, 12 clinically characterized by weakness, altered sensation and hyporeflexia/areflexia, evolving for more than 2 months. 13 The course of CIDP can be monophasic, relapsing-remitting or chronic progressive. 14 CIDP immunopathogenesis encompasses both humoral and cell-mediated immune responses, which contribute to demyelination and subsequent axonal damage causing neurological disability. 15 As we previously showed that defective Fas function may have a role in the development of CIDP and favor a severe disease evolution, 10 this work was aimed at extending the analysis to PRF1 variations to investigate their role in CIDP pathogenesis.
RESULTS AND DISCUSSION
We sequenced the coding region of PRF1 in 94 CIDP patients and 158 age-and gender-matched healthy controls searching for rare missense and nonsense variations, which would be lost by genome-wide association studies. We identified three missense variations-c.272C4T, c.11G4A and c.1153C4T-leading to the p.Ala91Val, p.Arg4His and p.Arg385Trp amino acid substitutions, respectively, and one nonsense variation, c.1267C4T, resulting in the premature stop codon p.Gln423Ter (Table 1) . p.Ala91Val was carried by 18 patients (16 heterozygotes) and 9 controls (all heterozygotes). p.Arg4His was detected in one heterozygous patient who was also heterozygous for p.Ala91Val; allele-specific PCR analysis showed that the two variations were located on different alleles. p.Gln423Ter and p.Arg385Trp were detected in one heterozygous patient each. p.Arg4His, p. Gln423Ter and p.Arg385Trp were not detected in controls.
All together, the genotypic frequency of these variations was significantly higher in patients than in controls and increased the risk of developing CIDP by 4.47-fold (Table 1) . Moreover, p. Ala91Val, by itself, increased the risk of developing CIDP by about 3.92-fold ( Table 2) .
The deleterious effect of p.Ala91Val has been documented by several studies showing that it causes decreased protein expression and partial loss of cytolytic activity. [16] [17] [18] The resulting protein is partly misfolded and may interfere with PRF expression and trafficking, so that it exerts a dominant negative effect on the function of the wild-type protein. 19 In heterozygous individuals, the wild-type allele may be underexpressed compared with the mutated allele, which further reduces CTL and natural killer function. 20 The frequency of p.Ala91Val is increased in patients with familial hemophagocytic lymphohistiocytosis, 2 autoimmune lymphoproliferative syndrome 4 and MS. 6 In our study, most patients carried this variation in heterozygosis, but in two patients (2%) it was found in homozygosis, which was not detected in our healthy controls and appeared to be quite rare (0.5%) in a previous Italian cohort of 1788 healthy subjects. 6 Also p.Arg4His, previously detected in a patient with acquired aplastic anemia, has been shown to decrease PRF expression and natural killer cell cytotoxic activity. 21 In contrast, no functional data are available on p.Arg385Trp, previously described in a patient with lymphoma. 22 Therefore, we performed an in silico analysis using four algorithms and showed that p.Arg385Trp was predicted to be deleterious by PolyPhen (prediction: probably damaging; score: 0.959), SIFT (prediction: not tolerated; score: 0.01) and pMUT (prediction: pathological; score: 0.7402), but not by SNAP (prediction: neutral; expected accuracy: 60%). These data suggest that p.Arg385Trp, too, may be deleterious, which is in line with its location into the cysteine-rich epidermal growth factor precursor-type domain (amino acids 356-386) that is highly conserved in humans, mice and rats. [23] [24] [25] Finally, the novel variation p.Gln423Ter is expected to lead to a truncated C2-domain of PRF, which may impair the binding of PRF to the plasma membrane of the target cell. 26 As novel stop codons may also affect RNA splicing, 27 we assessed this potential effect using the Human Splicing Finder algorithm. Results showed that p.Gln423Ter does not influence canonical splicing sites, but may create a novel binding site for the Ser/Argrich proteins involved in the splicing process. 28 Two further synonymous variations, c.822C4T and c.900C4T, were identified but their frequencies were similar among patients and controls and they were previously reported as common polymorphisms ( Table 1) .
Analysis of clinical variables showed that patients carrying PRF1 variations displayed increased frequency of relapsing forms (70 vs 37%) and axonal damage (85 vs 49%) compared with the other patients ( Table 3 ). In particular, the presence of PRF1 variations increases the risk of developing relapsing forms by fourfold and axonal damage by 5.3-fold. In contrast, no significant difference was detected in terms of gender distribution, disease duration, INCAT disability score, response to first and second line treatment, development of dysautonomia and central nervous system (CNS) involvement. However, a recent report showed that two young sisters carrying a functionally relevant PRF1 variation, namely p. Arg225Trp, presented relapsing-remitting ataxia caused by CNS inflammatory syndrome and triggered by recurrent infections. 29 This observation would suggest to extend the clinical evaluation to other variables, such as history of recurrent infections or presence of other autoimmune conditions, but these data were unfortunately not available. Furthermore, an accurate study of phenotype/genotype correlations would need the recruitment of a larger cohort of patients. Nonetheless, it should be noted that this study is one of the largest genetic association studies performed in CIDP to date. 30 Our findings are in line with the view that apoptotic mechanisms are crucial players in maintaining immune homeostasis in the nervous system. 11, [31] [32] [33] [34] Elegant studies on experimental autoimmune neuritis, an animal model of inflammatory neuropathy, showed that autoreactive T cells are eliminated by apoptosis. 35 Consistently, Bonetti et al. 36 showed that Schwann cells cultured in the presence of tumor necrosis factor α and those in nerve biopsies of CIDP patients express FasL and PRF, and can trigger apoptosis of T cells, which suggests that these cells are involved in protection of the nerve from immune attacks.
Previous work from our group showed that T cells from a substantial proportion of CIDP patients displayed defective Fasmediated apoptosis, which is involved in shutting off of the immune response, but this correlated with a progressive course. 10 Therefore, both the Fas and PRF defects are involved in CIDP development, but they have distinct effects on the disease course as the former favors the progressive course, whereas the latter a relapsing course.
This picture recalls our previous observations showing also that MS patients display increased frequency of missense variations of PRF1 and defective Fas function and the latter defect correlates with a progressive course of disease. 9 Although defective apoptosis may impair fratricide of autoreactive T cells, it should also be noted that both Fas and PRF are used by CTLs to counteract viral infections, which may have a role in CIDP development and course, and by autoimmune CTLs to damage the target tissues. Such an ambivalent role of apoptotic pathways may have different implications depending on the local context and disease stage. 31 In conclusion, this study shows that frequency of missense/ nonsense PRF1 variations is increased in CIDP patients. Although the relapsing course and axonal damage seems to be more 13 All patients underwent routine studies to rule out other causes of neuropathy, cerebrospinal fluid examination and neurophysiological evaluation (including motor and sensory conduction velocities, nerve and muscle action potentials, distal latencies, F-wave latencies and needle electromyography). Demyelinating, axonal or mixed forms were defined according to the electrodiagnostic criteria for peripheral nerve demyelination and axonal degeneration. 37 Patients were consecutively enrolled from the Neurology Departments of University of the Piemonte Orientale at Novara, University of Padua, University of Turin, and L Sacco Hospital, University of Milan.
The following clinical variables were collected in a common database: disease duration, course (monophasic, progressive, relapsing), INCAT disability score, 38 response to treatment (first and second line), dysautonomia, CNS involvement and axonal damage.
As a control group, we enrolled 158 healthy individuals, without firstsecond degree relatives affected by autoimmune diseases. Patients and controls were unrelated, Caucasian and Italian, matched for age and gender and analyzed in parallel. All subjects agreed to participate in the study, after reading and signing an informed consent form. The research was approved by the local Ethics Committee.
DNA analysis
Genomic DNA samples were isolated from the peripheral blood using standard methods and the entire coding region of PRF1 (exon 2 and exon 3) was amplified and sequenced as previously reported. 4 For allele-specific PCR the wild-type (4R) and mutant (4H) alleles were independently amplified using specific PCR amplification of genomic DNA. P.Arg4His and p.Ala91Val substitutions were typed by using the same primers.
Statistical analysis
Allelic frequencies were compared with Fisher's or Χ 2 -test with Yates' correction. Clinical features were compared using (a) Fisher's or Χ 2 -test with Yates' correction for gender, course, response to treatment, dysautonomia, central nervous system involvement and axonal damage; (b) Mann-Whitney U-test for age, disease duration and INCAT score. 38 All P-values were two-tailed and the significance cutoff was Po0.05. Putative functional significance of the nucleotide variations was evaluated with PolyPhen (http://genetics.bwh.harvard.edu/pph), pMUT (http://mmb2.pcb. ub.es:8080/PMut/), SIFT (http://sift.bii.a-star.edu.sg/sift-bin/), SNAP (http:// cubic.bioc.columbia.edu/services/SNAP/submit) and Human Splicing Finder (http://www.umd.be/HSF/). 
